Steward David L
Department of Otolaryngology-Head and Neck Surgery and The Neuroscience Institute, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, U.S.A.
Laryngoscope. 2004 Dec;114(12):2073-84. doi: 10.1097/01.mlg.0000149438.35855.af.
The primary objective is to determine the effectiveness of multilevel (tongue base and palate) temperature controlled radiofrequency tissue ablation (TCRFTA) for patients with obstructive sleep apnea syndrome (OSAS). The secondary objective is to compare multilevel TCRFTA to nasal continuous positive airway pressure (CPAP).
The study is a controlled case series of one investigator's experience with multilevel TCRFTA for patients with OSAS. Twenty-two subjects with mild to severe OSAS, without tonsil hypertrophy, completed multilevel TCRFTA (mean 4.8 tongue base and 1.8 palate treatment sessions) and had both pre- and posttreatment polysomnography. Primary outcomes included change from baseline in apnea/hypopnea index (AHI), daytime somnolence, and reaction time testing measured 2 to 3 months after TCRFTA. Secondary outcomes included change in other respiratory parameters, OSAS related quality of life, and upper airway size. Comparison of 18 patients treated with TCRFTA for mild to moderate OSAS (AHI > 5 and < or = 40) is made with 11 matched patients treated with nasal CPAP for mild to moderate OSAS.
Multilevel TCRFTA significantly improved AHI (P = .001), apnea index (P = .02), as well as respiratory and total arousal indices (P = .0002 and P = .01). Significant improvement with moderate or large treatment effect sizes were noted for OSAS related quality of life (P = .01) and daytime somnolence (P = .0001), with a trend toward significant improvement in reaction time testing (P = .06), with mean posttreatment normalization of all three outcome measures. Fifty-nine percent of subjects demonstrated at least a 50% reduction in AHI to less than 20. The targeted upper airway, measured in the supine position, demonstrated a trend toward significant improvement in mean cross sectional area (P = .05) and volume (P = .10). Side effects of TCRFTA were infrequent, mild, and self-limited. No significant correlation between pretreatment parameters and outcome improvement was noted. Nasal CPAP resulted in significant improvement in AHI (P = .0004) to near normal levels, with an associated improvement in OSAS related quality of life (P = .02) and a trend toward significant improvement in daytime somnolence (P = .06). Reaction time testing demonstrated no significant improvement (P = .75). No significant differences were seen for change in AHI, OSAS related quality of life, daytime somnolence, or reaction time testing between multilevel TCRFTA and CPAP.
Multilevel (tongue base and palate) TCRFTA is a low-morbidity, office-based procedure performed with local anesthesia and is an effective treatment option for patients with OSAS. On average, abnormalities in daytime somnolence, quality of life, and reaction time testing demonstrated improvement from baseline and were normalized after treatment. Polysomnographic respiratory parameters also demonstrated significant improvement with multilevel TCRFTA.
主要目的是确定多级(舌根和软腭)温度控制射频组织消融术(TCRFTA)对阻塞性睡眠呼吸暂停综合征(OSAS)患者的有效性。次要目的是将多级TCRFTA与鼻持续气道正压通气(CPAP)进行比较。
本研究是一项对照病例系列研究,基于一位研究者对OSAS患者进行多级TCRFTA的经验。22例无扁桃体肥大的轻至重度OSAS患者完成了多级TCRFTA(平均舌根治疗4.8次,软腭治疗1.8次),并在治疗前后均进行了多导睡眠图检查。主要结局包括TCRFTA术后2至3个月时,呼吸暂停/低通气指数(AHI)相对于基线的变化、日间嗜睡情况以及反应时间测试结果。次要结局包括其他呼吸参数的变化、OSAS相关生活质量以及上气道大小。将18例接受TCRFTA治疗的轻至中度OSAS(AHI>5且≤40)患者与11例匹配的接受鼻CPAP治疗的轻至中度OSAS患者进行比较。
多级TCRFTA显著改善了AHI(P = 0.001)、呼吸暂停指数(P = 0.02)以及呼吸和总觉醒指数(P = 0.0002和P = 0.01)。OSAS相关生活质量(P = 0.01)和日间嗜睡情况(P = 0.0001)有显著改善,治疗效果为中度或较大,反应时间测试有显著改善的趋势(P = 0.06),所有三项结局指标在治疗后平均恢复正常。59%的受试者AHI至少降低了50%,降至20以下。仰卧位测量的目标上气道,平均横截面积(P = 0.05)和体积(P = 0.10)有显著改善的趋势。TCRFTA的副作用很少见,程度较轻且为自限性。未发现治疗前参数与结局改善之间存在显著相关性。鼻CPAP使AHI显著改善(P = 0.0004)至接近正常水平,OSAS相关生活质量也有改善(P = 0.02),日间嗜睡情况有显著改善的趋势(P = 0.06)。反应时间测试无显著改善(P = 0.75)。多级TCRFTA与CPAP在AHI变化、OSAS相关生活质量、日间嗜睡情况或反应时间测试方面未发现显著差异。
多级(舌根和软腭)TCRFTA是一种在门诊进行的、采用局部麻醉的低发病率手术,是OSAS患者的一种有效治疗选择。平均而言,日间嗜睡、生活质量和反应时间测试方面的异常情况相对于基线有改善,并在治疗后恢复正常。多导睡眠图呼吸参数在多级TCRFTA治疗后也有显著改善。